Vaccines for Cancer Immunotherapy - 1st Edition - ISBN: 9780128140390

Vaccines for Cancer Immunotherapy

1st Edition

A Comprehensive Evidence-Based Review on Current Status and Future Perspectives

Editors: Nima Rezaei Mahsa Keshavarz-Fathi
Paperback ISBN: 9780128140390
Imprint: Academic Press
Published Date: 19th October 2018
Page Count: 198
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines.

Key Features

    • Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer
    • Presents the status of past and current vaccines for cancer treatment
    • Considers advantages and disadvantages of different therapeutic cancer vaccines
    • Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods
    • Analyzes obstacles to development of therapeutic cancer vaccines
    • Gives a view on future perspectives in the application of therapeutic cancer vaccines

    Readership

    Interdisciplinary: clinicians, scientists and researchers working on applying different modalities for cancer treatment, including biological therapies; immunologists, oncologists, biotechnologists, and other specialists dealing with cancer research and therapy

    Table of Contents

    1. Cancer immunology
      1. Innate and adoptive immunity
      2. MHC Class I and ǁ
      3. Tumor microenvironment

    2. General approaches in cancer immunotherapy
      1. Immune cells in cancer immunotherapy
      2. Active vs. Passive Immunotherapy

    3. Vaccines
      1. Definition
      2. Cancer vaccine
        1. Preventive cancer vaccine
        2. Therapeutic cancer vaccine

      3. Vectors
      4. Adjuvants
      5. Delivery system
      6. Route of administration

    4. Tumor antigens
      1. Targeting tumor antigens
      2. Epitope spreading
      3. Tumor associated antigens
        1. Definition
        2. Classification and examples

      4. Tumor specific antigens
        1. Definition
        2. Classification
        3. Neo antigens
        4. Shared antigens
        5. Unique antigens

      5. Glycolipids and Glycoproteins as antigens
      6. mono-epitope versus poly-epitope antigen

    5. The Strategy of Allogeneic and Autologous Cancer Vaccine
    6. Personalized Vaccine
    7. Whole Tumor Antigen Vaccine
      1. Tumor cell lysates
      2. Tumor-derived exosomes
      3. Irradiated gene-modified tumor cell lines
      4. Mechanism of Action
      5. Clinical trials
        1. Immune response
        2. Efficacy
        3. Adverse effects

      6. Advantages and disadvantages

    8. Protein and Peptide vaccines
      1. Mechanism of Action
      2. Clinical trials
        1. Immune response
        2. Efficacy
        3. Adverse effects

      3. Approved Vaccines
      4. Advantages and disadvantages

    9. Dendritic Cell vaccine
      1. Mechanism of Action
      2. Clinical trials
        1. Immune response
        2. Efficacy
        3. Adverse effects

      3. Approved Vaccines
      4. Advantages and disadvantages

    10. Genetic Vaccine
      1. Mechanism of Action
      2. DNA Vaccine
        1. Clinical trials
          1. Immune response
          2. Efficacy
          3. Adverse effects

      3. RNA Vaccine
        1. Clinical trials
          1. Immune response
          2. Efficacy
          3. Adverse effects

      4. Advantages and disadvantages

    11. Candidate cancers for vaccination
    12. The obstacles in development of Therapeutic Cancer Vaccine
      1. Tumor antigens
      2. Stage and progression of disease
      3. Prior treatments
      4. Clinical response versus immune response
      5. Designing clinical trials
      6. Other problems

    13. Combination Therapy
      1. Vaccine combined with other immunotherapeutic modalities
      2. Vaccine combined with other cancer treatments (Surgery /radiotherapy / chemotherapy)

    14. The Future Perspective for Therapeutic Cancer Vaccine
    15. Concluding remarks on Therapeutic Cancer Vaccine
    16. References

    Details

    No. of pages:
    198
    Language:
    English
    Copyright:
    © Academic Press 2018
    Published:
    Imprint:
    Academic Press
    Paperback ISBN:
    9780128140390

    About the Editor

    Nima Rezaei

    Nima Rezaei is Associate Professor of Clinical Immunology at Tehran University of Medical Sciences, Associate Dean of International Affairs in the School of Medicine, and Director of the Global Academic Program. He received his PhD in clinical immunology and human genetics from the University of Sheffield in the UK. He edits and writes for leading book series, and is the founder and advisor of two research interest groups, the Network of Immunity in Infection, Malignancy and Autoimmunity (NIMA) and the Cancer Immunology Project (CIP).

    Affiliations and Expertise

    Associate Professor of Clinical Immunology, Tehran University of Medical Sciences, Associate Dean of International Affairs in the School of Medicine, Tehran

    Mahsa Keshavarz-Fathi

    Mahsa Keshavarz-Farthi is a medical researcher at the Tehran University of Medical Sciences, and the managing director of Cancer Immunology Project (CIP), undertaking and managing different research project in the field of cancer immunology and immunotherapy. She is working on several research projects on immunotherapeutic modalities for cancer.

    Affiliations and Expertise

    Medical Researcher, Tehran University of Medical Sciences, Tehran

    Ratings and Reviews